Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.50 |
| ▸ | MYC | P01106 | 2/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | F7 | P08709 | 1/20 | 0.48 |
| ▸ | F3 | P13726 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | KMO | O15229 | 2/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30396748 | 1.00 | ALDH1A1 (0.65) | ALDH1A1TP53CA1CA2TSHR | |
| SCHEMBL392840 | 0.84 | SMN1; SMN2 (0.63) | ALDH1A1TP53CA1CA2TSHR | |
| SCHEMBL28072667 | 0.84 | ALDH1A1 (0.50) | ALDH1A1TP53CA1CA2TSHR | |
| SCHEMBL9692043 | 0.84 | ALDH1A1 (0.50) | ALDH1A1TP53CA1CA2TSHR | |
| SCHEMBL30349584 | 0.82 | ALDH1A1 (0.56) | ALDH1A1TP53CA1CA2TSHR | |
| SCHEMBL284068 | 0.82 | ALDH1A1 (0.56) | ALDH1A1TP53CA1CA2TSHR | |
| SCHEMBL1000440 | 0.81 | ALDH1A1 (0.71) | ALDH1A1TP53CA1CA2TSHR | |
| SCHEMBL19514758 | 0.81 | ALDH1A1 (0.71) | ALDH1A1TP53CA1CA2TSHR | |
| SCHEMBL10965676 | 0.80 | GRIK1 (0.54) | ALDH1A1TP53CA1CA2TSHR | |
| SCHEMBL3621421 | 0.80 | MAOB (0.47) | ALDH1A1TP53CA1CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 319 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114450275-B | Heteroaryl aminopyridine alcohol derivatives and pharmaceutical composition for preventing or treating autoimmune diseases comprising the same as active ingredient | 因诺沃治疗有限公司 | 2024-11-19 | — | — | CN | claimed |
| CN-113501807-A | Tetrahydrobenzothiophene compound, and preparation method and application of pharmaceutical composition | 重庆科技学院 | 2021-10-15 | — | — | CN | claimed |
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | claimed |
| CN-111548325-A | Preparation method of halogenated benzothiazepine compound, product prepared by preparation method and application of product | 西安都创医药科技有限公司 | 2020-08-18 | — | — | CN | claimed |
| EP-3551633-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2019-10-16 | — | — | EP | claimed |
| WO-2018108230-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2018-06-21 | — | — | WO | claimed |
| EP-2379558-B1 | NOVEL HETEROCYCLIC COMPOUNDS FOR USE AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-03-23 | — | — | EP | claimed |
| CN-104529735-A | 1-(5-bromo-4-chloro-2-fluorophenyl)-ethanone synthesis method | SUZHOU SHIYA BIOPHARMACEUTICALS INC | 2015-04-22 | — | — | CN | claimed |
| US-20110281859-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-17 | — | — | US | claimed |
| US-20110260051-A1 | METHOD FOR DETECTING TRACER COMPOUNDS FOR HYDROCARBON PRODUCTION | TOTAL S.A. (FR) | 2011-10-27 | — | — | US | claimed |
| EP-3433239-B1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12338241-B2 | Bicyclic sulfones and sulfoxides and methods of use thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| CN-116655497-B | Amidine derivative compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2025-06-03 | — | — | CN | disclosed |
| CN-114450275-B | Heteroaryl aminopyridine alcohol derivatives and pharmaceutical composition for preventing or treating autoimmune diseases comprising the same as active ingredient | 因诺沃治疗有限公司 | 2024-11-19 | — | — | CN | disclosed |
| WO-2003037346-A1 | 6-PHENYL-N-PHENYL-(1,3,5) -TRIAZINE-2,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOPHPHOSPHATIDIC ACID ACYLTRANSFERASE BETA (LPAAT-BETA) INHIBITORY ACTIVITY FOR USE IN THE TREATMENT OF CANCER | CELL THERAPEUTICS, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0295833-A1 | Aromatic-Spiropiperidine oxazepinones (and thiones) | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1988-12-21 | — | — | EP | disclosed |
| US-4746655-A | ANTIHISTAMINES | A. H. ROBINS COMPANY, INCORPORATED (US) | 1988-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338241-B2 | Bicyclic sulfones and sulfoxides and methods of use thereof | RB1, CCNE2, RPS3A | ALDH1A1 1912/4885TP53 64/4885CA1 2308/4885 |
| US-20110281859-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS | METAP2, METAP1, XPNPEP2 | ALDH1A1 1917/4885TP53 715/4885CA1 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.